Rodman & Renshaw Reiterates “Neutral” Rating for Viracta Therapeutics (NASDAQ:VIRX)

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “neutral” rating reiterated by stock analysts at Rodman & Renshaw in a research note issued to investors on Friday,Benzinga reports. They currently have a $0.25 target price on the stock, down from their previous target price of $3.50. Rodman & Renshaw’s price target suggests a potential upside of 56.25% from the stock’s current price.

Separately, Royal Bank of Canada cut their target price on Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $4.05.

Viracta Therapeutics Price Performance

Viracta Therapeutics stock opened at $0.16 on Friday. The stock has a market cap of $6.36 million, a PE ratio of -0.15 and a beta of 0.67. The stock’s fifty day moving average is $0.19 and its two-hundred day moving average is $0.31. Viracta Therapeutics has a 1-year low of $0.13 and a 1-year high of $1.31.

Hedge Funds Weigh In On Viracta Therapeutics

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 31.37% of the company’s stock.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.